A major study, just published this week, has challenged the widely held belief that individuals with Parkinson's disease respond better to deep brain stimulation (DBS) targeted to one particular site in the brain, the subthalamic nucleus (STN) compared to DBS targeted at another site in the brain, the globus pallidus interna (GPi). (Medical Device Daily)

Roche Diagnostics (Indianapolis) said the FDA has granted premarket approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. (Medical Device Daily)

In an effort to boost its presence in the vascular market, Covidien (Dublin, Ireland) said Tuesday it would buy ev3 (Plymouth, Minnesota) for $22.50 a share in cash, or $2.6 billion. (Medical Device Daily)